Clinical trial

A Measles, Mumps, and Rubella Investigational Vaccine Trial…

NCT00109278 · Merck Sharp & Dohme LLC, Industry · Completed

Key facts

NCT number NCT00109278
Title A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)
Official title A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin (rHA) Versus Currently Licensed V205C Manufactured From the 1967 Measles Stock Seed With Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of…
Lead sponsor Merck Sharp & Dohme LLC, Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Measles
Intervention type Biological
Interventions V205C, measles, mumps, and rubella virus vaccine live, Comparator: Measles, Mumps, and Rubella Virus Vaccine Live
Enrollment 1,100
Start date Oct 1, 2004
Primary completion May 1, 2005
Completion May 1, 2005
First posted Apr 26, 2005
Last update posted Mar 15, 2017

At a glance

  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies